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SHORT REPORT
Hormonal and reproductive factors and risk of glioma: A prospective cohort study
Stephanie A. Navarro Silvera1*, Anthony B. Miller2 and Thomas E. Rohan1
1Department of Epidemiology and Population Health, Albert Einstein College of Medicine, NY, USA
2Department of Public Health Sciences, University of Toronto, Toronto, Canada
The etiology of glioma, the most commonly diagnosed malignant
brain tumor among adults in the United States, is poorly under-
stood. Given the lower incidence rate of glioma in women than
in men, it has been hypothesized that reproductive and hormo-
nal factors may be involved in the etiology of glioma. We con-
ducted a secondary analysis of data from the National Breast
Screening Study, which included 89,835 Canadian women, aged
40–59 years at recruitment between 1980 and 1985. Linkages to
national cancer and mortality databases yielded data on cancer
incidence and deaths from all causes, respectively, with follow-
up ending between 1998 and 2000. Cox proportional hazards
models were used to estimate hazard ratios and 95% confidence
intervals (CI) for the association between hormonal and repro-
ductive factors and risk of glioma. During a mean of 16.4 years
of follow-up, we observed 120 incident glioma cases. Compared
with women with a relatively early age at menarche (12 years),
women who were 13–14 years of age at menarche had a 64%
increased risk of glioma (95% CI 5 1.01–2.65), and women who
were older than 14 years of age at menarche had a 66%
increased risk of glioma (95% CI 5 0.86–3.20, ptrend 5 0.06).
Age at first live birth, parity, menopausal status, use of oral con-
traceptive and use of hormone replacement therapy were not
associated with altered glioma risk in our study population.
Additional prospective studies are needed to confirm our find-
ings.
' 2005 Wiley-Liss, Inc.
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Glioma is the most commonly diagnosed malignant brain tumor
among adults in the United States,1,2 with an estimated 5-year
survival rate of 30%.2 Currently, ionizing radiation is the only
well-established risk factor for glioma.2,3 Beyond this, few other
risk factors for glioma have been established. However, incidence
rates of glioma are lower in women than in men.2 Furthermore,
steroid hormone receptors, particularly androgen receptors, are
expressed in gliomas,4,5 and Khalid et al.6 have demonstrated the
expression of estrogen-receptor-related antigen in human glioma
cells. As a result, it has been hypothesized that reproductive and
hormonal factors may be involved in the etiology of glioma.
The epidemiologic literature regarding reproductive and hormo-
nal factors and brain cancer risk is based primarily on case-control
studies.7–12 One cohort study, by Lambe et al.,13 has also exam-
ined some of these associations. Parity has been examined as a
risk factor for glioma in a number of studies, the findings for
which have been mixed, with 5 observing no association7,9–12 and
2 reporting inverse associations.8,13 Of the 5 studies that have
examined the role of age at first birth,8–10,13 3 observed no associa-
tion9,10,13 and 1, by Cantor et al.,8 reported a statistically signifi-
cant positive association, with risk of glioma. Additionally, no
association has been found with menopausal status.7,9,11,12 Few
studies have described the association between other reproductive
and hormonal factors and risk of glioma among women.7–13 To
our knowledge, the association between risk of glioma and age at
menarche, menopausal status, use of oral contraceptives and hor-
mone replacement therapy (HRT) use has not been examined in
any prospective cohort studies. Given the current lack of data from
prospective studies regarding these relationships, we examined the
association between reproductive and hormonal factors and
glioma risk in a cohort of Canadian women.
Material and methods
Study population
The design of our study has been described in detail else-
where.14 Briefly, 89,835 women, aged 40–59 years, were recruited
into the Canadian National Breast Screening Study between 1980
and 1985 from the general Canadian population by various means,
including personal invitation by letter, group mailings to employ-
ees of large institutions and to members of professional associa-
tions, advertisements in newspapers and public service announce-
ments on radio and television.15
Questionnaires
At recruitment into the cohort, participants completed self-
administered questionnaires that sought information on demo-
graphic characteristics, lifestyle factors, menstrual and reproduc-
tive history and use of oral contraceptives and replacement estro-
gens. Specifically, participants were asked questions about their
age at menarche, menopausal status, number of pregnancies last-
ing greater than 4 months (parity), age at first live birth, use of
HRT and use of oral contraceptives. Women who reported having
regular menstrual periods within the past 12 months were classi-
fied as premenopausal. Women whose menstrual periods ceased at
least 12 months before enrollment into the study and those who
had a bilateral oophorectomy were considered postmenopausal.16
Ascertainment of incident glioma cases and deaths
Incident cases of glioma (ICD-M codes 9380/3-9473/3 and
9490/0-9506/0) and deaths from all causes were ascertained
respectively by means of computerized record linkages to the
Canadian Cancer Database and to the National Mortality Data-
base, both of which are maintained by Statistics Canada. The link-
ages to the databases yielded data on cancer incidence and mortal-
ity (to December 31, 2000) for women in Ontario, (December 31,
1998) for women in Quebec and (December 31, 1999) for women
in other provinces. Table I provides information on the frequency
of the different histologic subtypes of glioma in our study popula-
tion.
Statistical analysis
Of the 89,835 women recruited into the study, we excluded
women with prevalent glioma at baseline (n 5 5), leaving 89,830
women available for analysis, amongst whom 120 incident cases
of glioma were observed. Participants with prevalent cancers (n 5
211) at baseline were not excluded from the analyses. We ran the
analyses with and without such subjects and the results were
essentially the same. For these analyses, study participants were
considered to be at risk from their date of enrollment until the date
of diagnosis of glioma, the termination of follow-up (the date to
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which cancer incidence data were available for women in the corre-
sponding province) or death, whichever occurred earlier. Cox pro-
portional hazards models (using age as the time scale) were used to
estimate hazard ratios (HR) and 95% confidence intervals (CI) for
the association between reproductive and hormonal factors and
glioma risk. All multivariate models included terms for study center
and randomization group (intervention or control). To test for trends
in risk with increasing levels of the exposures of interest, we either
assigned the categorical variables their ordinal number (parity) or
the category median (age at menarche, age at first live birth, duration
of oral contraceptive use and duration of HRT) and then fitted the
assigned value of each risk factor as a continuous variable in the risk
models. We then evaluated the statistical significance of the corre-
sponding coefficient, using the Wald test.17 Use of the lifetest proce-
dure in SASTM showed that the proportional hazards assumption fit-
ted the models used. All analyses were performed using SAS version
9 (SAS Institute Cary, NC).
Results
The average duration of follow-up for cohort members was 16.4
years (1,480,470 person-years). The mean (SD) age at baseline was
48.5 (5.6) (Table II) and the mean age at diagnosis for the cases was
60.0 (67.1) years. Compared with noncases, glioma cases tended to
be older, having an older mean age at menarche and were more likely
to be postmenopausal at baseline (data not shown).
Table III shows that in age-adjusted models parity was not asso-
ciated with altered risk of glioma. After multivariate adjustment,
the HRs remained essentially unchanged. Likewise, menopausal
status was not associated with glioma risk in both age- and multi-
variate-adjusted models. With respect to age at first birth, although
being 30 years of age or older at first live birth was associated with
a 32% increased risk of glioma, this finding was not statistically
significant (95% CI 5 0.69–2.50) (Table III). A statistically sig-
nificant 64% increased risk of glioma was found for women who
were 13–14 years of age at menarche compared with women who
experienced menarche before 13 years of age after adjusting for
age and other factors (95% CI 5 1.01–2.65), and those with
menarche after age 14 had a statistically nonsignificant 66%
increase in risk (95% CI 5 0.86–3.20); the associated test for
trend in risk with increasing age at menarche was of borderline
statistical significance (ptrend 5 0.06). Finally, exposure to exoge-
nous estrogen from either oral contraceptive use or use of HRT
was not associated with altered glioma risk (Table IV).
Discussion
The etiology of glioma is largely unknown. Other than ionizing
radiation, investigations have focused on the roles of lifestyle fac-
tors, such as diet, alcohol, and tobacco, and occupational expo-
sures, but have not yielded consistent findings.2 As indicated ear-
lier, there is some evidence that hormonal factors might influence
glioma risk, which has prompted investigations in the relationship
between hormonal and reproductive factors and glioma risk.
In the prospective study reported here, we found that risk of
glioma increased with increasing age at menarche, a trend of bor-
derline statistical significance. This supports findings by Hatch
et al.9 and Huang et al.,10 both of whom observed positive associ-
ations between age at menarche and risk of glioma. Our results
also are in keeping with evidence that age at menarche may be
inversely associated with estrogen levels among both pre- and
postmenopausal women18,19 and that, in animal models, estrogens
are neuroprotective, possibly via antioxidant effects or via activa-
tion of growth-signaling pathways.20,21 In addition, estrogen has
been shown to reduce glutamate toxicity in glial cells.22 Exposure
to estrogen due to early age at menarche may therefore act to pro-
tect against DNA damage to glial cells.
Of the 6 case-control studies7–12 that have examined the rela-
tionship between parity and risk of glioma, 5 found no significant
association7,9–12 while one8 observed a statistically significant
inverse association. In addition, Lambe et al.,13 who utilized
linked registry data from the Swedish Cancer Registry and a
nationwide Fertility Registry to conduct a nested case-control
study (1,657 incident cases) of brain tumors within a cohort of
9,942 women, found a statistically significant reduced risk of
glioma among ever-parous versus nulliparous women.
Our findings support the literature, which has largely found no
association between age at first live birth10,13 and risk of glioma.
Hatch et al.,9 in contrast, observed a statistically significant posi-
tive trend with increasing age at first live birth. Our findings also
support the literature, which has found no association between
menopausal status7,9,11,12 and risk of glioma. Further, our findings
regarding use of oral contraceptives are consistent with those of
Huang et al.,10 who likewise reported no association. While we
found no association between HRT and risk of glioma, Huang
et al.10 found a statistically nonsignificant inverse association
(OR5 0.73, 95% CI 5 0.49–1.10).
To our knowledge, ours is the first prospective cohort study to
examine the association between a range of reproductive and
hormonal factors, including parity, age at first live birth, age at
menarche, menopausal status and exogenous hormone use, and
risk of glioma. The main strength of this investigation is its pro-
spective study design, which eliminates the possibility of recall
bias. Also, the essentially complete follow-up of the cohort,23,24
based on linkage to national cancer incidence and mortality data-
bases, reduces the likelihood that our results reflect bias due to dif-
ferential follow-up.
One limitation is the fact that information on menopausal status
was collected only at baseline. Given that the minimum age at
baseline was 40 and that participants were followed up for 16
years, on average, it is more likely that most of those who were
premenopausal at enrollment would have become postmenopausal
during the course of follow-up. Therefore, it is quite likely that
our results for risk in association with premenopausal status at
recruitment are largely accounted for by a mix of gliomas diag-
TABLE II – BASELINE CHARACTERISTICS OF THE STUDY POPULATION
Factor n 5 89,830
Mean age at baseline (years) 48.56 5.6
Mean age at menarche (years) 12.86 2.2







HRT use (% ever)2 47.0
Oral contraceptives use (% ever) 58.5
1Among parous women only.–2HRT, hormone replacement ther-
apy; results among postmenopausal women only.










Giant cell glioblastoma 1
Glioblastoma with sarcomatous component 1
Oligodendroglioma, NOS 7
Oligodendroglioma, anaplastic type 1
Oligodendroblastoma 1
Total 120
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nosed pre- and postmenopausally. Additionally, information on
age at menopause was not collected, and we were, therefore,
unable to examine the relationship between age at menopause and
glioma risk. This may be of interest, given the possible association
between age at menarche and glioma, which may indicate an
effect of duration of exposure to endogenous hormones. Another
limitation is that only limited behavioral and biologic data were
collected beyond the recruitment date. As a result, we do not have
information on postenrollment patterns of HRT use among pre-
menopausal women, who became menopausal during follow-up,
and only limited information on subsequent hormone use for
women postmenopausal at enrollment.
In conclusion, the results of our study provide little support for
associations between hormonal and reproductive factors and risk
of glioma, with the possible exception of a positive association
between age at menarche and risk. Additional prospective studies
are needed to confirm our findings.
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